N4 Pharma PLC Changes to AGM (5821H)
March 25 2020 - 8:18AM
UK Regulatory
TIDMN4P
RNS Number : 5821H
N4 Pharma PLC
25 March 2020
25 March 2020
N4 Pharma plc
("N4 Pharma", the "Company" or the "Group")
Changes to AGM
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, announces an update on the Company's upcoming Annual
General Meeting ("AGM").
In light of the most recent advice from the Government to the
general public in response to the COVID-19 pandemic, it is clear
that the Company will not be able to proceed with the AGM on the
date and time anticipated. The Company has therefore decided to
withdraw the AGM notice for the meeting originally convened for 31
March 2020 and issue a new AGM notice for a meeting to be held at
10:00 a.m. on 23 April 2020 at the Company's offices at Weston
House, Bradgate Park View, Chellaston, Derby DE73 5U. The new
notice of AGM and proxy form will be sent to Shareholders in
respect of the reconvened AGM and copies will shortly be available
from the Company Reports section of the Company's website,
www.n4pharma.com .
The Company advises that only the formal business set out in the
notice of meeting will be considered at the AGM. The Company will
arrange for a separate presentation to Shareholders and Q&A to
be arranged via a webinar or video conference, the details of which
will be announced in due course. The Company is taking these
precautionary measures to safeguard Shareholders' health and to
make the AGM as safe and efficient as possible.
It is anticipated that the formal AGM to consider and vote upon
the various resolutions set out in the notice of meeting would be
attended only by two officers of the Company and all other officers
and advisers would not be in attendance. Shareholders are
discouraged from attending the AGM in person given the current
Government advice. Shareholders wishing to vote on any of the
matters of business are instead urged to do so via a completion of
a proxy form which can be completed and submitted to the Company.
Proxy votes already submitted in respect of the original AGM date
will not be valid at the reconvened AGM.
Proxies should be completed and returned in accordance with the
instructions on the form of proxy and the latest time for lodging
proxies is 10:00 a.m. on 21 April 2020. The completion and return
of a form of proxy will not preclude a member from attending in
person at the meeting and voting should the member wish to do so.
In order that any proxy votes of those members who choose to not
attend and vote in person are fully reflected in the voting on the
resolutions, the Chairman will direct that voting on all
resolutions set out in the notice of meeting will take place by way
of a poll. Under the Company's Articles, votes on a poll may be
given personally, by a corporate representative or by Proxy. Every
Shareholder who is present in person or by a corporate
representative or by Proxy shall have one vote for each share held
by them.
Enquiries:
N4 Pharma Plc
Nigel Theobald, CEO Via Scott PR
Allenby Capital Limited Tel: +44(0)203 328 5656
James Reeve/Asha Chotai
Scott PR Tel: +44(0)1477 539 539
Georgia Smith
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCMZGZFFKKGGZM
(END) Dow Jones Newswires
March 25, 2020 09:18 ET (13:18 GMT)
N4 Pharma (LSE:N4P)
Historical Stock Chart
From Apr 2024 to May 2024
N4 Pharma (LSE:N4P)
Historical Stock Chart
From May 2023 to May 2024